Please use this identifier to cite or link to this item:
https://accedacris.ulpgc.es/handle/10553/139757
| Title: | Molecular response with asciminib 20 mg QD in a patient intolerant to multiple TKIs | Authors: | Stuckey, Ruth Navarrete Bullon, Laura Borrero Borrego, Asuncion Ballester, Violeta Vidal Rodriguez-Medina, Carlos Morales Curbelo, Alejandro Gonzalez Pinedo, Leslie Torres Ochando, Melissa Veiga Vaz, Alvaro Perera, Maria del Mar Bilbao Sieyro, Cristina López Rodríguez, Juan Francisco Segura Díaz, Adrian Gómez Casares, María Teresa |
UNESCO Clasification: | 32 Ciencias médicas 3209 Farmacología 320708 Hematología |
Keywords: | Asciminib Tyrosine Kinase Inhibitors (Tkis) Cytopenia Subtherapeutic Dosing |
Issue Date: | 2025 | Journal: | Annals of Hematology | Abstract: | This case highlights a young CML patient who achieved a major molecular response (MMR) after just four months with a subtherapeutic dose of asciminib. The patient could not tolerate full-dose asciminib, or the full dose of two previous tyrosine kinase inhibitors (TKI) due to myelotoxicity, but blood counts recovered rapidly upon TKI suspension and reduced dosing enabled sustained treatment. This is the second reported case of the use of 20 mg QD asciminib, four times below the recommended dose, and the first to demonstrate efficacy at this dose. The study emphasizes asciminib's potential for overcoming treatment challenges associated with multi-resistant/intolerant CML patients. | URI: | https://accedacris.ulpgc.es/handle/10553/139757 | ISSN: | 0939-5555 | DOI: | 10.1007/s00277-025-06339-5 | Source: | Annals Of Hematology[ISSN 0939-5555], v. 104, pp. 3007-3009 (Abril 2025) |
| Appears in Collections: | Artículos |
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.